Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Lipodystrophy Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Lipodystrophy Overview | 7 | 1 |
| Lipodystrophy Therapeutics under Development by Companies | 8 | 1 |
| Lipodystrophy Pipeline Products Glance | 9 | 2 |
| Late Stage Products | 9 | 1 |
| Early Stage Products | 10 | 1 |
| Lipodystrophy Products under Development by Companies | 11 | 1 |
| Lipodystrophy Companies Involved in Therapeutics Development | 12 | 5 |
| Aegerion Pharmaceuticals, Inc. | 12 | 1 |
| Akcea Therapeutics Inc | 13 | 1 |
| Ambrx, Inc. | 14 | 1 |
| Amunix Operating Inc. | 15 | 1 |
| Bolder Biotechnology, Inc. | 16 | 1 |
| Lipodystrophy Therapeutics Assessment | 17 | 8 |
| Assessment by Monotherapy Products | 17 | 1 |
| Assessment by Target | 18 | 2 |
| Assessment by Mechanism of Action | 20 | 2 |
| Assessment by Route of Administration | 22 | 1 |
| Assessment by Molecule Type | 23 | 2 |
| Drug Profiles | 25 | 14 |
| AMX-342 Drug Profile | 25 | 1 |
| ARX-328 Drug Profile | 26 | 1 |
| BBT-031 Drug Profile | 27 | 1 |
| metreleptin Drug Profile | 28 | 5 |
| volanesorsen sodium Drug Profile | 33 | 6 |
| Lipodystrophy Product Development Milestones | 39 | 11 |
| Featured News &Press Releases | 39 | 1 |
| Jul 28, 2016: Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy | 39 | 1 |
| Jun 27, 2016: Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes | 39 | 1 |
| May 29, 2014: Zydus Explores Newer Treatment Options With its Breakthrough Drug, Lipaglyn | 40 | 1 |
| Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease | 41 | 1 |
| Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin | 42 | 1 |
| Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin | 42 | 1 |
| May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy | 43 | 1 |
| Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy | 43 | 1 |
| Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy | 44 | 1 |
| Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy | 45 | 1 |
| Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy | 46 | 1 |
| Apr 15, 2011: Amylin To Present Data Showing Investigational Metreleptin Treatment Led To Long-Term Improvements In Diabetes And Lipid Control In Patients With Lipodystrophy | 47 | 1 |
| Dec 20, 2010: Amylin Submits Clinical And Nonclinical Sections Of Rolling Biologics License Application For Metreleptin To Treat Rare Forms Of Lipodystrophy | 48 | 1 |
| Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants | 48 | 1 |
| Dec 16, 2008: Bolder BioTechnology Receives $1.9 million NIH Grant To Continue Development of Long-Acting Growth Hormone Product BBT-031 | 49 | 1 |
| Appendix | 50 | 2 |
| Methodology | 50 | 1 |
| Coverage | 50 | 1 |
| Secondary Research | 50 | 1 |
| Primary Research | 50 | 1 |
| Expert Panel Validation | 50 | 1 |
| Contact Us | 50 | 1 |
| Disclaimer | 51 | 1 |
